Antiviral Agents

Preface

References

Contributors

Chapter One. Antiviral Agents for Herpes Simplex Virus

Abbreviations

1 Introduction

2 Historical Overview: Therapies for HSV Infections

3 Clinical Experience with ACV, VACV, and FCV Through Two Decades

4 Antiviral Drug Resistance

5 Novel Approaches to HSV Chemotherapy

6 Prospects for Novel Antiviral Compounds and Vaccines

7 Conclusion

Conflict of Interest

References

Further Reading

Chapter Two. Nucleotide Prodrugs for the Treatment of HCV Infection

Abbreviations

1 Introduction

2 Nucleoside Inhibitors

3 Nucleotide Prodrugs

4 Conclusion

Conflict of Interest

References

Chapter Three. HIV Integrase Inhibitors: 20-Year Landmark and Challenges

Abbreviations

1 Introduction

2 Requirement of IN for HIV Replication

3 IN Structure

4 The INSTIs

5 Challenges

6 Conclusion

Conflict of Interest

References

Chapter Four. Advances in the Treatment of Varicella-Zoster Virus Infections

Abbreviations

1 Introduction

2 Vaccination Strategies and Postexposure Prophylaxis

3 Existing Antiviral Treatments

4 Medical Need for New Anti-VZV Agents

5 Development of Novel Anti-VZV Agents

6 Candidate Anti-VZV Drugs

7 Perspectives

8 Conclusion

Conflict of Interest

Acknowledgments

References

Chapter Five. Hepatitis C Virus: Standard-of-Care Treatment

Abbreviations

1 Introduction

2 Curing HCV Infection

3 Interferons

4 Ribavirin

5 Direct HCV Inhibitors (DAAs and HTAs)

6 Interferon-Based Strategies in 2013

7 Interferon-Free Regimens in 2014 and Onward

8 Conclusion

Conflict of Interest

References

Chapter Six. Influenza Virus Resistance to Antiviral Therapy

Abbreviations

1 Introduction

2 Antiviral Drugs Under Development

3 Resistance to Antiviral Therapy

4 Mechanisms of Resistance to NAIs

5 Permissive and Compensatory Mechanisms Governing Primary Resistance

6 Effectiveness of NAIs

7 Conclusion

Conflict of Interest

References

Further Reading

Chapter Seven. The Natural Course of Chronic Hepatitis B Virus Infection and Its Management

Abbreviations

1 Introduction

2 A Flashback from the Discovery of HBV to the Recognition of the Wide Spectrum of Chronic HBV Infection

3 Development of Chronic HBV Infection and the Phases in Its Natural Course

4 Complicating and Associated Conditions and Comorbidities

5 Treatment of CHB

6 Future Treatments for CHB

7 Conclusion

Conflict of Interest

References

Chapter Eight. The Holý Trinity: The Acyclic Nucleoside Phosphonates

Abbreviations

1 Introduction

2 HPMPA

3 Cidofovir

4 Adefovir

5 Tenofovir

6 Tenofovir Combinations

7 Tenofovir for the Prevention of HIV Infections

8 Tenofovir for the Treatment of HBV Infections

9 Tenofovir for PMTCT

10 Tenofovir Toxicity

11 GS-7340, GS-9131, GS-9191, GS-9219

12 Conclusion

Conflict of Interest

Acknowledgments

References

Chapter Nine. The Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors in the Treatment of HIV Infections (AIDS)

Abbreviations

1 Introduction

2 Reverse Transcriptase

3 Nucleoside Reverse Transcriptase Inhibitors

4 Nonnucleoside Reverse Transcriptase Inhibitors

5 Protease Inhibitors

6 Drug Combinations

7 Clinical Aspects

8 Preexposure Prophylaxis

9 Prevention of Mother-to-Child Transmission

10 Children

11 Toxicity

12 Adherence (Compliance)

13 Resistance

14 New NRTIs, NNRTIs, and PIs

15 Conclusion

Conflict of Interest

Acknowledgments

References

Index